National Taiwan University

Academia Sinica

Advpharma, Inc.

National Health Research Institutes

Other

The University of North Carolina at Chapel Hill

National Yang Ming Chiao Tung University

Taipei Medical University

National Chung Hsing University

Taichung Veterans General Hospital

Wo, Andrew Man, Chung

Pan-Chyr Yang

Konan Peck

Tse-Ming Hong

Ting-Jen Rachel Cheng

Jeremy J W Chen

Chi-Huey Wong

Rong-Jie Chein

Wei-Yun Lai

Huei-Wen Chen

Sung-Liang Yu

Wan-Jiun Chen

Yi-Chung Chang

Cheng-Wen Wu

Hsuan-Yu Chen

Bo-Tsang Huang

Shuenn-Chen Yang

Szu-Hua Pan

Yuh-Ling Chen

Yi-Jen Lee

Gee-Chen Chang

Yi-Ying Wu

Ang Yuan

Cheng-Chung Wu

Jin-Yuan Shin

Bing-Ching Ho

Jin-Yuan Shih

Ming-Shiu Lin

Ting-Hung Rachel Chou

Kuo-Hsiung Lee

Che-Ming Teng

Jim-Min Fang

Kenneth F Bastow

Qian Shi

Din Ping Tsai

Chi-Yuan Chen

Chi-Ying Huang

Yuan Luo

Reen Wu

Jane Hsiao

Harn-Jing Terng

Pei-Ying Lin

Jian-Wei Chen

Cheng-Ju Chang

Fu Sheng Chang

Xiaoming Yang

Ling-Wei Li

Chun-Nan Lee

Shauh-Der Yeh

Yeh-Tze Chou

Chih-Yi Chen

Ker-Chau Li

Yuh-Pyng Sher

Meng-Hua Lee

Jen-Wei Wang

Yi-Wen Chu

Shu-Li Wung

Provided herein are compounds of Formula (I). The disclosure provides new compounds, compositions, and methods for treating, delaying, and/or preventing the adverse effects of proliferative diseases, such as cancers including, for example, lung cancer, breast cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, head and neck cancer, or leukemia (e.g., cancer resistant to treatment by one or more microtubule-targeting agents (e.g., cancer resistant to multiple drugs associated with P-glycoprotein (P-gp) overexpression)). Provided are methods of inhibiting polymerization of a cancer cell microtubule in a subject in need thereof or a cell, tissue, or biological sample, binding β-tubulin, inhibiting microtubule assembly and, inducing apoptosis in a cancer cell resistant to multiple drugs in a tissue, biological sample, or subject. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for treating any of the target diseases described herein.

Methods of using 4(1)-quinolone derivatives

Provided herein are methods and kits for analyzing a sample such as a biological sample obtained from a subject having, suspected of having, or being at risk for a cancer to assess presence of cancer stem cells in the sample, which is indicative of poor cancer prognosis.

Biomarkers for lung cancer stem cells

The present invention provides a device for generating an abrupt autofocusing beam, comprising a light source module, a metasurface phase modulating element, and a focus lens, wherein the light source module generates an incident light beam, the metasurface modulating element has a first optical receiving surface for receiving the incident light beam, and an optical emitting surface having a plurality of dielectric nano-structures formed thereon for modulating the incident light beam into a diffracted light beam wherein the plurality of nano-structures respectively corresponding to optical-phase mask patterns, and the focus lens is arranged at a side of the optical receiving surface for performing optical Fourier transform of the diffracted light beam obtained from the metasurface phase modulating element.

Metasurface based device for generating abrupt autofocusing beam

The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).

4,9-dioxo-4,9-dihydronaphtho[2,3-B]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases

Methods for treating cancer and/or reducing sternness of cancer stem cells in a subject using a CD14 antagonist, which may be an anti-CD14 antibody.

Method for treating cancer using CD14 antagonists

An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.

Method for identifying anti-cancer agents using an in vitro cell culture system that maintains cancer cell stemness

Compounds of Formula (I) and methods for treating, delaying, and/or preventing the adverse effects of proliferative diseases, such as cancers including, for example, lung cancer, breast cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, head and neck cancer, or leukemia (e.g., cancer resistant to treatment by one or more microtubule-targeting agents, e.g., cancer resistant to multiple drugs associated with P-glycoprotein (P-gp) overexpression). Methods of inhibiting polymerization of a cancer cell microtubule in a subject in need thereof or a cell, tissue, or biological sample, binding &#x3b2;-tubulin, inhibiting microtubule assembly and, inducing apoptosis in a cancer cell resistant to multiple drugs in a tissue, biological sample, or subject. Pharmaceutical compositions, kits, and methods of using the compounds for treating any of the target diseases described herein. 

4(1H)-quinolone derivatives and uses thereof

Nucleic acid aptamers that bind to tumor necrosis factor alpha (TNF). Also provided herein are pharmaceutical compositions comprising such anti-TNF aptamers and methods for the using the same for therapeutic and diagnostic applications, for example, alleviating liver injury and monitoring presence of TNF in vivo or in vitro.

TNF-targeting aptamers and uses thereof for treatment or diagnosing TNF-related inflammatory diseases

The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections). 

4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases

The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. The PINK1-CTD polypeptide inhibits, prevents and/or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressing cancer therapy.

PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment

The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and/or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine.

Pharmaceutical composition for treatment of cancer using phenothiazine

The present disclosure provides compounds of Formulas (I') and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases. 

Purine compounds possessing anticancer activity

Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.

Antagonistic PDL1 aptamers and their applications in cancer therapy

Aptamers that bind to and inhibit CTLA-4 and uses thereof in enhancing immune activities, and treating cancer and HIV infection are provided.

Antagonistic CTLA-4 aptamers and applications thereof in enhancing immune activity

Growing community of inventors

Taipei, Taiwan

Pan-Chyr Yang